Triglyceride-Rich Lipoproteins (TRL)
| Catalog # |
B2010392 |
| Lot # |
Batch Dependent |
| Expiration |
Batch Dependent |
| Amount |
100 mg |
| Concentration |
12,000–16,000 mg/dL |
| Supplied as |
Solution |
| Appearance |
Yellow/Orange |
| Applications |
Triglyceride interference testing in immunoassays |
| Storage |
–20°C |
| Keywords |
Human triglycerides, TRL, HTF, TRIG, TAG |
| Grade |
Biotechnology grade; ≥95% purity; 0.22 µm filtered |
This highly concentrated solution of Triglyceride-Rich Lipoproteins (TRL) is purified from human plasma and formulated for interference testing in immunoassays. With a triglyceride concentration range of 12,000–16,000 mg/dL, this reagent enables rigorous evaluation of assay performance under hyperlipidemic conditions. TRLs are known to impact immunoassay accuracy due to their size, density, and lipid content, making them essential for validating robustness and specificity.
Supplied as a yellow/orange solution in 100 mg aliquots, this biotechnology-grade material is filtered through 0.22 µm membranes and stored at –20°C. All solid components meet a minimum purity threshold of 95%, and solutions are prepared using Type I ultrapure water (resistivity >18 MΩ·cm). Ideal for clinical chemistry labs, assay developers, and diagnostic manufacturers seeking to simulate high-triglyceride interference scenarios.
Key benefits:
- Purified TRL fraction for interference testing in immunoassays
- Concentration range: 12,000–16,000 mg/dL
- Filtered and aliquoted for reproducibility and long-term storage
- Prepared in ultrapure water; biotechnology grade
- Supports validation of assay specificity under hyperlipidemic conditions
Indication for Use:
This product is for Research Use Only (RUO). This product is not for administration to humans or animals. This product is not for human or veterinary diagnostic or therapeutic use.
References:
1: Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL,
Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L,
Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A,
Watts GF; European Atherosclerosis Society Consensus Panel. Triglyceride-rich
lipoproteins and high-density lipoprotein cholesterol in patients at high risk
of cardiovascular disease: evidence and guidance for management. Eur Heart J.
2011 Jun;32(11):1345-61.
2: Duran EK, Aday AW, Cook NR, Buring JE, Ridker PM, Pradhan AD. Triglyceride-
Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident
Cardiovascular Disease. J Am Coll Cardiol. 2020 May 5;75(17):2122-2135.
3: Botham KM, Wheeler-Jones CP. Postprandial lipoproteins and the molecular
regulation of vascular homeostasis. Prog Lipid Res. 2013 Oct;52(4):446-64.
4: Davidson MH. Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly
stepsister of LDL-C. Eur Heart J. 2018 Feb 14;39(7):620-622.
5: Sun CJ, McCudden C, Brisson D, Shaw J, Gaudet D, Ooi TC. Calculated Non-HDL
Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in
Hypertriglyceridemia. J Endocr Soc. 2019 Nov 3;4(1):bvz010.
6: Wolska A, Dunbar RL, Freeman LA, Ueda M, Amar MJ, Sviridov DO, Remaley AT.
Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in
triglyceride metabolism. Atherosclerosis. 2017 Dec;267:49-60.
7: Khetarpal SA, Zeng X, Millar JS, Vitali C, Somasundara AVH, Zanoni P, Landro
JA, Barucci N, Zavadoski WJ, Sun Z, de Haard H, Toth IV, Peloso GM, Natarajan P,
Cuchel M, Lund-Katz S, Phillips MC, Tall AR, Kathiresan S, DaSilva-Jardine P,
Yates NA, Rader DJ. A human APOC3 missense variant and monoclonal antibody
accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
Nat Med. 2017 Sep;23(9):1086-1094.
8: Zhang Y, He W, He C, Wan J, Lin X, Zheng X, Li L, Li X, Yang X, Yu B, Xian X,
Zhu Y, Wang Y, Liu G, Lu N. Large triglyceride-rich lipoproteins in
hypertriglyceridemia are associated with the severity of acute pancreatitis in
experimental mice. Cell Death Dis. 2019 Sep 30;10(10):728.
